[23] It should be noted that some inhibitor patients, particularly those not on immune tolerance with fVIII, may have a memory B-cell response to fVIII infusions potentially boosting inhibitor titers. Recent data in our laboratory has shown that the epitope specificity and inhibitor kinetics within the C2 domain are more important than inhibitor titer in predicting the response to fVIII. [14] Additionally in the absence of anti-fVIII inhibitors, even 1% fVIII supplementation to rfVIIa improved the ETP, peak thrombin and index velocity of thrombin generation in hemophilia A plasma. The gene discussed is F8; the disease is hemophilia A.